Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=8cad575f-9ff4-42d7-bce6-711c261571ae
Date 11/4/2015
Company Name Kura Oncology
Mailing Address 11119 North Torrey Pines Road La Jolla, CA 92037 USA
Company Description At Kura Oncology (NASDAQ: KURA), we are committed to realizing the promise of precision medicines for cancer. The genomics revolution is transforming how we treat cancer.
Proceeds Purposes We currently expect that we will use the net proceeds from this offering as follows: to fund the completion of our Phase 2 clinical trials of tipifarnib in patients who have solid tumors with HRAS mutations and in patients with PTCL; to fund our planned Phase 2 clinical trial of tipifarnib in patients with lower risk MDS; to fund our ongoing ERK inhibitor program; to fund the initiation of our companion diagnostic program to aid in the selection of patients with HRAS mutant tumors and for additional indications; to fund research and preclinical development of our other product candidates; and for general corporate purposes, including general and administrative expenses, capital expenditures, working capital and prosecution and maintenance of our intellectual property.